Enables Advancement of First-In-Class Anti-Inflammatory
Antibody Programs Through Key Clinical Studies
SAN DIEGO, California — AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an oversubscribed $40MM Series D financing round. Participants in this financing round include BVF Partners L.P. and its affiliates, BioMed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors.
Proceeds from the financing are intended to advance AnaptysBio’s first-in-class anti-IL-33 and anti-IL-36 receptor antibody programs through key Phase II studies. The financing will also support the continued discovery of novel therapeutic antibodies against emerging target biology in inflammation and immuno-oncology using AnaptysBio’s proprietary somatic hypermutation-based antibody discovery platform.
“The proceeds of this financing provide AnaptysBio with the financial strength to potentially demonstrate efficacy of our anti-IL-33 program in severe adult asthma and peanut allergy patients, while also advancing our anti-IL-36 receptor program to proof-of-concept in generalized pustular psoriasis,” said Hamza Suria, President & CEO of AnaptysBio. “We are pleased to welcome such highly respected investors to our shareholder base. Their investment provides strong endorsement of the quality of our pipeline, platform and the team we have built at AnaptysBio.”